Although there is an encouraging signal for PI3K/AKT/mTOR activation in acute leukemia, clinical efficacy of inhibition has been disappointingly modest so far and it is becoming clear that as monotherapy, pharmacological interruption of PI3K/AKT/mTOR will only be successful in a subgroup of patients. Here, PIK3CA is linked to acute leukemia.